alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
APPLICATION 

UNDER THE 

SMALL 

COMMUNITY 

AIR 

SERVICE 

DEVELOPMENT 

PROGRAM

COUNTY OF 

VENTURA/OXNARD 

AIRPORT

Summary Information

A. Applicant Information: 

(Check all that apply)

X Not a Consortium Interstate Consortium Intrastate Consortium

Community now receives EAS subsidy

Community (or Consortium member) previously received a Small 

Community Grant; If previous recipient: N/A

B. Public/Private Partnerships: 

(List organization names)

Public Private

1. Ventura County Dept of Airports 1. Economic Develop. of Oxnard

2. Oxnard Airport Authority 2. Oxnard Chamber of Commerce

3. City of Oxnard 3. Oxnard Conv. & Visitors Bureau

4. City of Ventura 4. Ventura Chamber of Commerce

5. Ventura Conv. & Visitors Bureau

6. Gold Coast Broadcasting

7. KCLU Radio

8. Ventura County Lodging Assoc.

C. Project Proposal: 

(Check all that apply)

X Marketing X Start-Up Cost Offset

X Travel Bank Secure Additional Service

Surface Transportation X New Route

X Launch New Carrier Subsidy

Study X Revenue Guarantee

Upgrade Aircraft First Service

X Service Restoration Other (explain below): Regional Service

D. Existing Landing Aids at Local Airport:

X Full ILS X Published Instrument Approach

X Localizer X Outer/Middle Marker

X Other (specify): GPS

E. Project Cost:

Line Description

Sub

Total

Total

Amount

1 Federal amount requested $500,000

2 State cash financial contribution $0

Local cash financial contribution

3a Airport cash funds $45,000

3b Non-airport cash funds $50,000

3 Total local cash funds (3a+3b) $95,000

4 TOTAL CASH FUNDING (1+2+3) $595,000

In-Kind contribution

5a Airport In-Kind contribution** $98,013

5b Other In-Kind contribution** $300,000

5 TOTAL IN-KIND CONTRIBUTION 

(5a+5b) $398,013

6 TOTAL PROJECT COST (4+5) $993,013

F. In-Kind Contributions:

For funds in lines 5a (Airport In-Kind contribution) and 5b (Other In-Kind contribution), 

please describe the source(s) of fund(s) for each.

5a Fee waivers

5b Marketing and Airline Travel Bank®

G. Is this application subject to review by State under Executive Order 

12372 process?

a. This application was made available to the State under the Executive 

Order 12372. Process for review on (date) _____________.

b. Program is subject to E.O. 12372, but has not been selected for 

review.

c. Program is not covered by E.O. 12372.

H. Is the Applicant delinquent on any Federal debt? (if “yes”, provide 

explanation)

No

Yes (explain)

X

X
IN THE SUPREME COURT OF PENNSYLVANIA EASTERN DISTRICT COMMONWEALTH OF PENNSYLVANIA, Petitioner

v. KEISHA JONES, Respondent : : : : : : : : : : : No. 580 EAL 2014 Petition for Allowance of Appeal from the Order of the Superior Court

ORDER PER CURIAM AND NOW , this 6th day of May, 2015, the Petition for Allowance of Appeal is DENIED
.
Draft petroleum coke MACT floor spreadsheet 

 Bill Maxwell 

 to: Cortney_Higgins 

 03/04/2011 03:41 PM 

 Cc: RobertJ Wayland 

 

Floor analysis_petcoke_030411.xlsx 

Deliberative Document -- FOIA Exempt

Bill Maxwell 

Energy Strategies Group 

Sector Policies and Programs Division 

U.S. EPA Mail Code D243-01 

109 T.W. Alexander Drive 

Research Triangle Park, NC 27711 

Phone: 919-541-5430 

FAX: 919-541-5450
UNPUBLISHED

UNITED STATES COURT OF APPEALS

FOR THE FOURTH CIRCUIT

No. 05-6804

UNITED STATES OF AMERICA,

Plaintiff - Appellee,

versus

KEVIN EUGENE JONES,

Defendant - Appellant.

Appeal from the United States District Court for the Middle

District of North Carolina, at Greensboro. James A. Beaty, Jr.,

District Judge. (CR-94-300; CA-04-1114)

Submitted: September 29, 2005 Decided: October 11, 2005

Before WILKINSON, KING, and GREGORY, Circuit Judges.

Dismissed by unpublished per curiam opinion.

Kevin Eugene Jones, Appellant Pro Se.

Unpublished opinions are not binding precedent in this circuit.

See Local Rule 36(c).
- 2 -

PER CURIAM:

Kevin Eugene Jones seeks to appeal the district court's

order accepting the magistrate judge's recommendation to dismiss

his successive motion pursuant to 28 U.S.C. § 2255 (2000) for lack

of jurisdiction. An appeal may not be taken from the final order

in a post-conviction proceeding unless a circuit justice or judge

issues a certificate of appealability. 28 U.S.C. § 2253(c)(1)

(2000). A certificate of appealability will not issue absent “a

substantial showing of the denial of a constitutional right.” 28

U.S.C. § 2253(c)(2) (2000). A prisoner satisfies this standard by

demonstrating that reasonable jurists would find that his

constitutional claims are debatable and that any dispositive

procedural rulings by the district court are also debatable or

wrong. See Miller-El v. Cockrell, 537 U.S. 322, 336 (2003); Slack

v. McDaniel, 529 U.S. 473, 484 (2000); Rose v. Lee, 252 F.3d 676,

683 (4th Cir. 2001). We have independently reviewed the record and

conclude that Jones has not made the requisite showing.

Accordingly, we deny Jones’ motion for a certificate of

appealability and dismiss the appeal. We dispense with oral

argument because the facts and legal contentions are adequately

presented in the materials before the court and argument would not

aid the decisional process.

DISMISSED
|   | (1)  the      Report fully complies with the requirements of Section 13(a) or 15(d), as      applicable, of the Securities Exchange Act of 1934,  and |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | (2)  the      information contained in the Report fairly presents, in all material      respects, the financial condition and results of operations of the Company      at the dates and for the periodsindicated. |
|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Date:        | May 12, 2009 |   | By:     | /s/ Patrick E. Delaney |
|--------------|------------------------|--------|--------------|---------------------------------------|
|    |              |   |    | Patrick E. Delaney          |
|    |              |   |    | Chief Financial Officer     |

----
August 25 , 2016



### JUDGMENT 

## The Fourteenth Court of Appeals

TYRIQUE AMOR EVANS , Appellant

NO. 14

- 16

- 00002

- CR V.

THE STATE OF TEXAS , Appellee

________________________________ This cause was heard on the transcript of the record of the court below. Having considered the record, this Court holds that there was no error in the judgment. The Court orders the judgment AFFIRMED

. We further order appellant pay all costs expended in the appeal.

We further order this decision certified below for observance.
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 3017 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 3017

      To extend the temporary suspension of duty on Spiromesifen.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 8, 2012

 Mr. Menendez introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
      To extend the temporary suspension of duty on Spiromesifen.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SPIROMESIFEN.

    (a) In General.--Heading 9902.10.71 of the Harmonized Tariff 
Schedule of the United States (relating to Spiromesifen) is amended by 
striking the date in the effective period column and inserting ``12/31/
2015''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
with respect to goods entered, or withdrawn from warehouse for 
consumption, on or after the 15th day after the date of the enactment 
of this Act.
                                 <all>
```
<PAGE>

                  GENWORTH LIFE INSURANCE COMPANY OF NEW YORK
                      OPTIONAL DEATH PROCEEDS ENDORSEMENT

This endorsement is effective on the Contract Date. It amends the Death
Provisions section by deleting the Amount Payable When Death Occurs Before
Annuity Commencement Date provision and adding the following:

Amount Payable When Death Occurs Before Annuity Commencement Date

Amount Payable upon the Death of an Owner or Joint Owner Who Is Not Also an
Annuitant: The amount payable is the Contract Value on the first Valuation Day
that we have received Proof of Death.

Death Benefit provisions upon the Death of an Annuitant or Joint Annuitant: The
amount payable (the "Death Benefit") is the greater of (a) and (b), where:

    (a)is Purchase Payments adjusted as stated below for any withdrawals and
       premium tax; and

    (b)is the Contract Value on the first Valuation Day that we have received
       Proof of Death.

Withdrawals reduce the Death Benefit proportionally by the same percentage that
the withdrawal, including any surrender charges and premium taxes, reduces the
Contract Value.

For Genworth Life Insurance Company of New York,

                                                  [/s/ David J. Sloane
                                                  ------------------------------
                                                  David J. Sloane
                                                  President]

NY5344 3/07                           1
Major Structures: 1. Primary alcohols: H 3 C - (CH 2 ) X - OH, where: X= 11 through 23 2. Esters: R - C(O)OR', where: R and R' are the predominant even numbered carbon chains indicated below: Total Carbon number (R - C(O)OR') R R' C24 12 12 C26 12 - 14 12 - 14 C28 12 - 16 12 - 16 C30 12 - 18 12 - 18 C32 12 - 20 12 - 20 C34 12 - 22 12 - 22 C36 12 - 22 14 - 24 C38 12 - 22 16 - 26 C40 16 - 24 16 - 24 C42 18 - 24 18 - 24 C44 22 - 24 20 - 22 C46 22 24
<TABLE> <S> <C>

<ARTICLE> 5

<S>                             <C>
<PERIOD-TYPE>                   6-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               JUN-30-2000
<CASH>                                             535
<SECURITIES>                                         0
<RECEIVABLES>                                   98,661
<ALLOWANCES>                                   (63,885)
<INVENTORY>                                     54,589
<CURRENT-ASSETS>                               252,663
<PP&E>                                       1,128,890
<DEPRECIATION>                                (198,482)
<TOTAL-ASSETS>                               9,262,316
<CURRENT-LIABILITIES>                        2,021,890
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        24,073
<OTHER-SE>                                   6,819,675
<TOTAL-LIABILITY-AND-EQUITY>                 9,262,316
<SALES>                                        382,130
<TOTAL-REVENUES>                               382,130
<CGS>                                          469,397
<TOTAL-COSTS>                                  469,397
<OTHER-EXPENSES>                             6,139,019
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              22,264
<INCOME-PRETAX>                             (6,248,550)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                         (6,248,550)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                (6,248,550)
<EPS-BASIC>                                      (0.27)
<EPS-DILUTED>                                    (0.27)


</TABLE>
##### 



[ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
 EXHIBIT 10.67
    
 RE:     Drug Discovery Collaboration Agreement
  InterMune Array Agreement
    1.
    
    InterMune shall pay to Array [ * ] in cash; and2.
    
    Following Arrays receipt of such cash payment and in the spirit of Section
4.2.1 of the Agreement, Array shall immediately (i) effectuate the [ * ] to InterMune
of [ * ] which claims the composition of matter of chemical compounds, one of which
shall be [ * ] in accordance with the Agreement [ * ], and (ii) have the continuing
obligation to [ * ] to InterMune any Collaboration Patent containing a Valid Claim
covering the composition of matter of such Lead Compound (and any Product containing
such Lead Compound) or a method of using or a method of making such Lead Compound in
accordance with the Agreement. In the event




---



##### 



InterMune [ * ], InterMune shall, at Arrays request, [ * ] to Array [ * ] to
InterMune under this letter agreement.
     
 Acknowledged and Agreed:ARRAY BIOPHARMA INC.By:
    
    /s/ David L. SnitmanName:
    
    David L. SnitmanTitle:
    
    COODate:
    
    3-14-05cc:
    
    General Counsel, Array BioPharma
 [ * ] = Certain information on this page has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions.
 2
```

[Congressional Bills 112th Congress]
[From the U.S. Government Publishing Office]
[S. 3136 Introduced in Senate (IS)]

112th CONGRESS
  2d Session
                                S. 3136

       To extend the temporary reduction of duty on Imidacloprid.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 10, 2012

  Mrs. Hagan introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
       To extend the temporary reduction of duty on Imidacloprid.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. IMIDACLOPRID.

    (a) In General.--Heading 9902.10.32 of the Harmonized Tariff 
Schedule of the United States (relating to Imidacloprid) is amended by 
striking the date in the effective period column and inserting ``12/31/
2015''.
    (b) Effective Date.--The amendment made by subsection (a) applies 
to goods entered, or withdrawn from warehouse for consumption, on or 
after the 15th day after the date of the enactment of this Act.
                                 <all>
```
steam_record - Re: Milford Power Project - Plant ID 02542 - Request for Extension 

 

Greetings, 

This e-mail is a confirmation that your extension request for the steam electric effluent 

guidelines questionnaire was received. Extension requests will be evaluated on a case-by-case 

basis. Please be aware that submittal of an extension request to EPA does not alter the due date

of your questionnaire unless and until EPA agrees to the extension and establishes a new date.

Sincerely, 

-----Mike Cartney <mcartney@cpv.com> wrote: ----- 

To: Jezebele Alicea/DC/USEPA/US@EPA 

From: Mike Cartney <mcartney@cpv.com> 

Date: 07/08/2010 09:54AM 

cc: Tom Favinger <tfavinger@cpv.com> 

From: <Alicea.Jezebele@epamail.epa.gov>

To: Mike Cartney <mcartney@cpv.com>

Date: 7/9/2010 12:25 PM

Subject: Re: Milford Power Project - Plant ID 02542 - Request for Extension

Page 1 of 2

file://C:\Documents and Settings\TMedley\Local Settings\Temp\XPgrpwise\4C37152CDO... 8/24/2011
Subject: Milford Power Project - Plant ID 02542 - Request for Extension 

Jezebele,

Milford Power requests an extension for the filing of the ICR. Milford is still in the 

process of completing its FERC/NERC mandated reliability audit and planning for some 

significant maintenance activities in the fall.

Due to the above circumstances, Milford wishes to request the maximum extension 

possible.

Thanks,

Michael Cartney

Milford Power Company LLC

Vice President and Plant Manager

Phone (203) 882-1010 Ext 227

Fax (203) 882-1515

 

Page 2 of 2

file://C:\Documents and Settings\TMedley\Local Settings\Temp\XPgrpwise\4C37152CDO... 8/24/2011
INITIAL REVIEW ENGINEERING REPORT ID Number: P-04-0346/0347

ENGINEER: Prothero / AMO / WRL PV (kg/yr):
SUBMITTER:

USE:.

OTHER USES:

MSDS: Label:

General Eqp.:

Respirator:
Health Effects: TLV/PEL (PMN or raw materials):

CRSS (3/1/2004): Chemical Name: **346:**
**347:**

VP:
S-H 2 O:

MW: Phys State:

Consumer Use:INITIAL REVIEW ENGINEERING REPORT ID Number: P-04-0346/0347

SAT (3/2/2004): Migration to groundwater: negligible PBT rating: P2B1T1 Health: 1-2; inhalation, **dermal**

Eco: **3; all releases to water** 

OCCUPATIONAL EXPOSURE RATING: 1-2

NOTES & KEY ASSUMPTIONS:

POLLUTION PREVENTION CONSIDERATIONS:

EXPOSURE-BASED REVIEW: Not requiredINITIAL REVIEW ENGINEERING REPORT ID Number: P-04-0346/0347

USE:

Number of Sites: 3-5 user sites (submission, estimates are
based on **3** sites) Days/yr: 60 (submission)

Process Description:

ENVIRONMENTAL RELEASES (Eqpt. cleaning, container residue, etc.):

**Land or Incineration or Water: <<4.1 kg/day over 60 days/yr for 4 sites or 1000 kg/yr** 
**from:**

**to: Basis:** INITIAL REVIEW ENGINEERING REPORT ID Number: P-04-0346/0347

USE: (cont.)

OCCUPATIONAL EXPOSURE Tot. # of workers: Days/yr:

Inhalation:

**Dermal:**
II 

112TH CONGRESS 

2D SESSION S. 2558 

To extend the temporary suspension of duty on artichokes, prepared or 

preserved otherwise than by vinegar or acetic acid, not frozen. 

IN THE SENATE OF THE UNITED STATES 

MAY 7, 2012 

Mrs. FEINSTEIN introduced the following bill; which was read twice and 

referred to the Committee on Finance 

A BILL 

To extend the temporary suspension of duty on artichokes, 

prepared or preserved otherwise than by vinegar or acetic 

acid, not frozen. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. ARTICHOKES, PREPARED OR PRESERVED OTH4 ERWISE THAN BY VINEGAR OR ACETIC ACID, 

5 NOT FROZEN. 

6 (a) IN GENERAL.—Heading 9902.03.89 of the Har7 monized Tariff Schedule of the United States (relating to 

8 artichokes, prepared or preserved otherwise than by vin9 egar or acetic acid, not frozen) is amended by striking the 


rfrederick on DSK6VPTVN1PROD with BILLS
2 

•S 2558 IS

1 date in the effective period column and inserting ‘‘12/31/ 

2 2015’’. 

3 (b) EFFECTIVE DATE.—The amendment made by 

4 subsection (a) applies with respect to goods entered, or 

5 withdrawn from warehouse for consumption, on or after 

6 the 15th day after the date of the enactment of this Act. 

Æ 


rfrederick on DSK6VPTVN1PROD with BILLS
IN THE SUPREME COURT OF THE STATE OF MONTANA

No. DA 22-0014

IN THE MATTER OF:

M.T.H.,

Respondent and Appellant.

ORDER

Upon consideration of Appellant’s motion for extension of time, and 

good cause appearing,

IT IS HEREBY ORDERED that Appellant is granted an extension 

of time to and including May 30, 2022, within which to prepare, file, 

and serve Appellant’s opening brief on appeal.

Electronically signed by:

Mike McGrath

Chief Justice, Montana Supreme Court

April 21 2022

04/21/2022

Case Number: DA 22-0014
II 

112TH CONGRESS 

2D SESSION S. 3276 

[Report No. 112–174] 

To extend certain amendments made by the FISA Amendments Act of 2008, 

and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

JUNE 7, 2012 

Mrs. FEINSTEIN, from the Select Committee on Intelligence, reported the 

following original bill; which was read twice and placed on the calendar 

JUNE 29, 2012 

Referred to the Committee on the Judiciary pursuant to section 3(b) of 

S. Res. 400 of the 94th Congress, as amended by S. Res. 445 of the 108th 

Congress 

A BILL 

To extend certain amendments made by the FISA 

Amendments Act of 2008, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘FAA Sunsets Exten5 sion Act of 2012’’. 


smartinez on DSK6TPTVN1PROD with BILLS
2 

S 3276 RCS

1 SEC. 2. EXTENSION OF FISA AMENDMENTS ACT OF 2008 

2 SUNSET. 

3 (a) EXTENSION.—Section 403(b)(1) of the FISA 

4 Amendments Act of 2008 (Public Law 110-261; 50 U.S.C. 

5 1881 note) is amended by striking ‘‘December 31, 2012’’ 

6 and inserting ‘‘June 1, 2017’’. 

7 (b) TECHNICAL AND CONFORMING AMENDMENTS.— 

8 Section 403(b)(2) of such Act (Public Law 110-261; 122 

9 Stat. 2474) is amended by striking ‘‘December 31, 2012’’ 

10 and inserting ‘‘June 1, 2017’’. 

11 (c) ORDERS IN EFFECT.—Section 404(b)(1) of such 

12 Act (Public Law 110-261; 50 U.S.C. 1801 note) is amend13 ed in the heading by striking ‘‘DECEMBER 31, 2012’’ and 

14 inserting ‘‘JUNE 1, 2017’’. 

Æ 


smartinez on DSK6TPTVN1PROD with BILLS
EXHIBIT 32.1


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT BY
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection  with the Quarterly  Report of GFR  Pharmaceuticals,  Inc. on Form
10-QSB for the period ending  September  30, 2005, as filed with the  Securities
and Exchange  Commission on the date hereof (the  "Report"),  I, Richard Pierce,
Chief Executive Officer of the Company,  certify,  pursuant to 18 U.S.C. Section
1350,  as adopted  pursuant  to Section 906 of the  Sarbanes-Oxley  Act of 2002,
that, to the best of my knowledge and belief:

         (1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

         (2) The  information  contained in the Report fairly  presents,  in all
material  respects,  the  financial  condition  and result of  operations of the
Company.



By: /s/ Richard Pierce
Richard Pierce
CEO, Director
(Principal Executive Officer)

Date: November 21, 2005

A signed  original of this written  statement  required by Section 906, or other
document authenticating, acknowledging, or otherwise adopting the signature that
appears in typed form within the  electronic  version of this written  statement
has been  provided  to the  Company  and will be  retained  by the  Company  and
furnished to the Securities and Exchange Commission or its staff upon request.